Search
Meet Eva Hellström-Lindberg, our Volunteer of the Month
Can you tell us what you do for EHA and when you started?
These days I am not as involved in EHA as I used to be, besides the various services when asked for, which I think is how it should…
Meet Stefan Fröhling, our November volunteer of the month
Can you tell us what you do for EHA and when you started?
I first learned about EHA in 2002 when I attended the 7th Congress of EHA in Florence.
Meet Stefan Fröhling, our November volunteer of the month
Can you tell us what you do for EHA and when you started?
I first learned about EHA in 2002 when I attended the 7th Congress of EHA in Florence.
Meet Robert Hills, our August volunteer of the month
Can you tell us what you do for EHA and when you started?
I’m a relatively recent volunteer for EHA, as I only started working with them on their Clinical Research Training in Hematology (CRTH) program in 2016.
Meet Robert Hills, our August volunteer of the month
Can you tell us what you do for EHA and when you started?
I’m a relatively recent volunteer for EHA, as I only started working with them on their Clinical Research Training in Hematology (CRTH) program in 2016.
Meet Ton Hagenbeek, our May volunteer of the month
Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.
Read moreMeet Ton Hagenbeek, our May volunteer of the month
Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.
Read moreHospital pharmacists and regulators lead the way on shortages
EHA welcomes initiatives but calls for more focus on causes
Medicine shortages have a negative impact on the quality and cost of treatments and on patient access to the best possible care.
Does the patient with myelofibrosis feel better through Pacritinib?
Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.
Read moreHighlights of the EHA-EMA Joint Symposium on RWE
The fourth EHA-EMA Joint Symposium at EHA2024 brought together investigators, regulators and patients to discuss the use of real world evidence (RWE) in the evaluation of new drugs.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- »